TrialPhase 3 Study to Treat Patients With Soft Tissue Sarcomas
Trial details
- Registry ID
- NCT02049905
- Phase
- Phase 3
Drug research
Investigator's Choice Treatment (Darcabazine, Pazopanib, Gemcitabine + Docetaxel, Doxorubicin, Ifosfamide)
Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.
Drug identity checked against registry records
Also recorded as Darcabazine; Doxorubicin; Gemcitabine + Docetaxel; Ifosfamide; Pazopanib
A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.
Included trials
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Phase 3 Study to Treat Patients With Soft Tissue SarcomasNCT02049905 | IBRX | Phase 3 | Completed | 2017-05Actual |
Regulatory dates and decisions
| No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed. |